Endologix, maker of minimally invasive devices to treat vascular diseases, has rebranded as Rhevera Medical. In a news release posted yesterday, the Santa Rosa, California–based company said the name combines “rheo,” Greek for flow, and “vera,” Latin for true. According to the company, the name expresses its tech focus on providing true, sustained blood flow […]
Endologix
Endologix acquires Pounce thrombectomy system from Surmodics
Endologix announced today that it acquired the Pounce thrombectomy system from Surmodics, closing the deal on May 18. Pounce, an FDA-cleared and commercially available fully mechanical thrombectomy platform, offers the non-surgical removal of thrombi and emboli from peripheral arteries. It comes in multiple configurations to support use across a range of peripheral arterial vessel sizes. […]
Endologix brings on former Silk Road Medical exec as CCO
Endologix announced today that it appointed Andrew Davis as its new chief commercial officer (CCO), effective immediately. Davis joins with experience in commercial leadership, most recently serving as CCO at Silk Road Medical. There, he spearheaded the go-to-market strategy for Silk Road’s carotid artery disease therapy before Boston Scientific acquired the company for $1.2 billion […]
Endologix picks former Medtronic executive as new CEO
Endologix announced today that President and CEO Dr. Matt Thompson intends to step down and take on a new role. Thompson plans to transition into the position of EVP and chief medical officer. As a result, the company appointed Dr. John Liddicoat as its new president and CEO, effective immediately. Richard Mott, Endologix’s board chair, […]
Endologix reports positive 3-year Detour PAD treatment data
Endologix announced the final 36-month results for the DETOUR2 study evaluating its Detour system for treating peripheral arterial disease (PAD). Detour features the EndoCross device and Torus stent grafts. It enables physicians to bypass lesions in the superficial femoral artery by using stents routed through the femoral vein. This restores blood flow to the leg, […]
Endologix hires Medtronic executive as COO
Endologix today announced it appointed Graham Philips as chief operating officer, effective immediately. In this new role, Philips will oversee manufacturing, supply chain, R&D, and quality at the vascular-disease-treating devices company. He’ll report to CEO Matt Thompson. “I am delighted to welcome Graham to Endologix. His proven leadership and extensive operational expertise will be invaluable […]
Endologix picks former Medtronic leader as new chief commercial officer
Endologix announced today that it appointed Mike Mathias as its new chief commercial officer (CCO), effective immediately. Mathias brings 30 years of experience leading commercial organizations within the cardiovascular area. He most recently served as VP of commercial operations at Limflow. He held that role from 2022 until Inari Medical acquired the chronic limb-threatening ischemia […]
Endologix completes first procedures using Detour system to kick off U.S. launch
Endologix announced today that the first patients underwent a procedure using its Detour system since it received FDA approval. The FDA approved Detour for use in percutaneous transmural arterial bypass (PTAB) to treat peripheral arterial disease (PAD) last month. This initial procedure marks the official start of the company’s targeted market release of Detour in […]
2-year data supports Endologix Detour system for treating PAD
About a week after garnering FDA approval, Endologix announced positive 24-month data for its Detour system for treating PAD. Irvine, California–Endologix picked up premarket approval on June 7 for its Detour system to treat long, complex superficial femoropopliteal lesions. The DETOUR2 study evaluated the system’s performance in percutaneous transmural arterial bypass (PTAB). This approach aims […]
FDA approves new Endologix peripheral arterial disease treatment
Endologix recently announced it received FDA approval for its Detour system to treat long, complex superficial femoropopliteal lesions. Company officials describe the Detour system as a breakthrough in the treatment of peripheral arterial disease (PAD), which the CDC estimates affected roughly 6.5 million Americans over 40. The present recommended therapy is open surgical bypass, an […]
Endologix wins CE mark for abdominal aortic aneurysm system
Endologix announced today that it received CE mark approval for its AFX2 endovascular abdominal aortic aneurysm (AAA) system. Irvine, California-based Endologix designed the AFX2 system with unique sealing technology that preserves native bifurcation to provide durable outcomes and personalized repair for AAA patients. “CE Mark certification under the new [EU MDR] requirements is a high-bar […]
